tors, 5-chloro-2, 4-dihydroxypyridine [CDHP; a potent dihydropyrimidine dehydrogenase (DPD) inhibitor] and potassium oxonate (OXO; an orotate phosphoribosyl transferase inhibitor), at a molar ratio of 1 : 0.4 : 1, with the two modulators added in order to enhance antitumor effects via increasing the blood 5-FU concentration and reducing digestive toxicity [1, 2] . Two late phase II studies demonstrated the effi cacy of singleagent therapy with S-1 for gastric cancer; the response rates were 49% (25/51) and 44% (19/43), respectively; these rates being high for single-agent anticancer therapy [3, 4] . In addition, S-1 is an oral preparation, and this route may be advantageous for patients undergoing chemotherapy. Thus, in Japan, single-agent therapy with S-1 has been emphasized as a standard treatment for advanced or recurrent gastric cancer. In 2007, the Japan Clinical Oncology Group (JCOG) presented the results of a randomized phase III study (JCOG 9912) including S-1 monotherapy at the annual meeting of the American Society of Clinical Oncology (ASCO); the effi cacy of S-1 showed signifi cant noninferiority to that of 5-FU alone. S-1 was recognized as a potent oral antitumor agent [5] .
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Irinotecan (CPT-11) is also an antitumor agent developed in Japan; its action mechanism involves the inhibition of topoisomerase I [6] . Concerning the effi cacy of CPT-11 monotherapy for advanced gastric cancer, the response rates were 19.0% (4/21) and 18.4% (14/76), respectively, in early and late phase II studies in Japan [7, 8] . This agent may be useful for treating advanced or recurrent gastric cancer. Various combination therapies incorporating CPT-11 have been studied in clinical trials in Japan, especially combinations with cisplatin (CDDP) and S-1, and the potent antitumor effects of these combinations have been confi rmed [9] [10] [11] [12] [13] . Based on these results, two randomized phase III studies were conducted in Japan. In this article, I focus on combination therapy with S-1 and CPT-11 for advanced or recurrent gastric cancer, and review the results of phase Introduction S-1, an oral 5-fl uorouracil (FU) derivative developed in Japan in 1999, consists of tegafur (FT) and two modula-I/II clinical studies of combination therapy with S-1 and CPT-11 that were conducted in Japan [10] [11] [12] [13] . In addition, I discuss the current and future perspectives of this combination therapy, based on the results of a randomized phase III study (S-1 vs S-1 + CPT-11; GC0301/TOP 002) reported at the Gastrointestinal Cancer Symposium in 2008 [14] .
Theoretical background of combination therapy with S-1 and CPT-11 in gastric cancer
The action mechanism of fl uoropyrimidines differs from that of CPT-11, and animal experimental studies have demonstrated the effects of fl uoropyrimidine and CPT-11 combination therapy [15] . In colorectal cancer patients, combination therapy with CPT-11 and 5-FU (such as FOLFIRI regimen) was effective [16, 17] . In gastric cancer patients, the combination of fl uoropyrimidines and CPT-11 may also be useful. Takiuchi et al. [18] reported that S-1 plus CPT-11 showed an augmented antitumor effect against 5-FU-resistant tumors with high thymidylate synthase (TS) activity, compared to CPT-11 alone and S-1 alone in an experimental study. A potential mechanism of this effect was suggested by the signifi cant reduction in TS activity observed in tumors with high TS activity following CPT-11 administration (Fig. 1) [18] . Ichikawa et al. [19] in vestigated the mRNA expression of TS and a 5-FUmetabolizing enzyme, DPD, in their series, and indicated that many patients with low-level TS expression responded to S-1 alone, whereas a high proportion of patients with S-1-resistant tumors (some of whom had high-level TS-expression) responded to the combination of S-1 and CPT-11. On the other hand, both Takiuchi et al. [18] and Ichikawa et al. [19] reported that there was no relationship between high or low DPD mRNA expression and tumor response to either S-1 monotherapy or to combination therapy with S-1 and CPT-11. Fluoropyrimidines are a mainstay of palliative treatment for advanced or recurrent gastric cancer. S-1 has a theoretical advantage over 5-FU in terms of having antitumor activity that appears to be independent of the level of DPD expression, suggesting that S-1 should be active in tumors expected to be resistant to 5-FU on the basis of high DPD expression. Moreover, the combination of S-1 and CPT-11 should also be active in tumors expected to be resistant to S-1 monotherapy on the basis of high TS expression. Based on this theoretical background, several phase I/II clinical studies of combination therapy with S-1 and CPT-11 were conducted.
Phase I/II clinical studies of combination therapy with S-1 and CPT-11
The results of the main phase I/II studies of combination therapy with S-1 and CPT-11 in patients with advanced or recurrent gastric cancer in Japan are summarized in Table 1 . Komatsu et al. [10] ) twice daily (standard dose in Japan), followed by 2 weeks without treatment. Even at level 3, the MTD was not reached. However, at level 1, marked bone marrow suppression was noted in 1 patient. Therefore, the Efficacy and Safety Committee recommended that the recommended dose (RD) of CPT-11 should be established as 125 mg/m 2 . In a phase II study, 24 patients with measurable lesions were enrolled. A total of 91 cycles were administered (median, 5.9 cycles). The response rate was 54% (13/24), and the median survival time (MST) was 581 days. The main grade 3 or higher side effects included neutropenia (60%) and nausea/vomiting (27%).
Takiuchi et al. [11] conducted a phase I study to determine the MTD and RD of CPT-11, given on days . No dose-limiting toxicity (DLT) was observed at either level 1, 2, or 3. At dose level 4, three of six patients exhibited DLTs in the fi rst course; one of the three patients had grade 3 diarrhea, and the other two patients had grade 3 rash; all three skipped the second administration of CPT-11 on day 15 because of delayed resolution of grade 2 leukopenia. The RD of CPT-11 in combination with S-1 was the dose of 80 mg/ m 2 at level 3 according to the protocol defi nitions [11] . In a phase II study, 23 patients were enrolled to investigate the effi cacy and safety of the combination. The response rate, median time to progression (TTP), and MST were 47.8% (11/23), 210 days, and 394 days, respectively. The incidence of grade 3 or 4 hematological and nonhematological toxicities was 17.4% and 8.4%; the toxicities included neutropenia (8.7%), anemia (8.7%), diarrhea (4.3%), anorexia (4.3%), and nausea/vomiting (4.3%); the incidences of severe toxicities were generally low [12] .
Inokuchi et al. [13] conducted a phase I study to estimate the MTD of CPT-11, given on days 1 and 8 in combination with S-1 administered at a fi xed dose of 40 mg/m 2 twice daily on days 1-14, followed by 2 weeks' rest. The cycle was repeated every 4 weeks. The doses of CPT-11 investigated were 70, 80, 90, and 100 mg/m 2 . At 100 mg/m 2 , DLT was noted in two of three patients. Initially, the RD was established as 90 mg/m 2 . According to subsequent follow-up data, grade 4 bone marrow suppression was observed at 90 mg/m 2 in all three patients in the second course. Therefore, the RD was fi nally established as 80 mg/m 2 . In a phase II study, 51 patients were registered to estimate the effi cacy and safety of the CPT-11 and S-1 combination. The response rate and MST were 61% (31/51) and 444 days, respectively. Grade 3 or higher side effects were neutropenia (14%), anorexia (10%), nausea (7%), and vomiting (5%) [13] .
Although there were slight differences in the administration schedules, these phase II studies showed response rates of more than 50% and MSTs exceeding 1 year when a CPT-11 and S-1 combination was given as fi rst-line treatment in patients with advanced or recurrent gastric cancer. In terms of toxicity profi les, the administration schedule employed by Takiuchi et al. [11] was considered to be more acceptable than the schedules reported by Komatsu et al. [10] and Inokuchi et al. [13] . Based on these results, a randomized phase III trial has been conducted to evaluate the effi cacy of combination therapy with S-1 and CPT-11 in improving survival, compared with that of S-1 monotherapy, for advanced or recurrent gastric cancer (GC0301/TOP 002).
Current status and future perspectives of combination therapy with S-1 and CPT-11
The results of the GC0301/TOP 002 (S-1 vs S-1 + CPT-11) trial were announced by Imamura et al. [14] at the Gastrointestinal Cancer Symposium in 2008. The primary endpoint was overall survival (OS), and the secondary endpoints were time to treatment failure, 1-year survival rate, response rate, and safety. The followup period was 1.5 years. In patients evaluable according to the response evaluation criteria in solid tumors (RECIST), the response rates were 26.9% in the S-1 monotherapy arm and 41.5% in the combination therapy of S-1 and CPT-11 arm, with the difference being statistically signifi cant (P = 0.035). The 1-year survival rate was 44.9% in the S-1 monotherapy arm and 52.0% in the combination therapy of S-1 and CPT-11 arm. In the two arms, the main grade 3 or higher side effects consisted of neutropenia (S-1 vs S-1 + CPT-11; 10.6% vs 26.6%), diarrhea (S-1 vs S-1 + CPT-11; 5.6% vs 15.8%), anorexia (S-1 vs S-1 + CPT-11; 9.9% vs 15.8%), nausea (S-1 vs S-1 + CPT-11; 3.7% vs 7.0%), and vomiting (S-1 vs S-1 + CPT-11; 0.6% vs 2.5%). The incidences of severe toxicity were slightly higher in the combination of S-1 and CPT-11 arm, but the toxicity was tolerable in both arms. The MST in the S-1 monotherapy arm was 318 days and that in the combination of S-1 and CPT-11 arm was 389 days; however, at 1.5-year follow up, the OS in the combination of S-1 and CPT-11 arm did not signifi cantly exceed that in the S-1 monotherapy arm [P = 0.23; hazard ratio (HR) = 0.89]. It was concluded that, considering that 68 patients (22%) were censored (mainly due to unexpectedly long survival times in both arms), further follow-up would be needed to confi rm the OS with more precision.
On the other hand, as it was announced -at the annual meeting of ASCO in 2007 (SPIRITS trial) -that combination therapy with S-1 and CDDP significantly prolonged OS compared to S-1 monotherapy, it seems that CPT-11 may not be the best partner in combination with S-1 at present [20] . In a previous study comparing CPT-11 plus 5-FU/folinic acid (IF) with 5-FU plus CDDP (FP), OS in the IF arm did not exceed that in the FP arm, leading to the conclusion that IF would be the treatment choice for patients in whom CDDP administration is not possible for some reason [21] . In addition, in the JCOG 9912 trial reported by Boku et al. [5] in 2007, at the annual ASCO meeting, combination therapy with CPT-11 and CDDP did not show statistically signifi cant superiority to 5-FU monotherapy, in terms of OS. Therefore, at present, no CPT-11-based regimens can be recommended as fi rst-line treatment for advanced or recurrent gastric cancer. However, the report of the GC0301/TOP002 trial is not a fi nal result, and further follow-up of the censored cases is still underway. In the near future, the fi nal report of this trial should help us to resolve the question of the use of CPT-11 for treating gastric cancer.
